BIOCRYST PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M | $17.8M | $48.8M | $20.7M |
| Cost of Revenue | $19.1M | $12.3M | $4.5M | $6.4M | $7.2M | $1.6M | $3.7M | — |
| Gross Profit | $855.8M | $438.4M | $326.9M | $264.4M | $149.9M | $16.3M | $45.1M | — |
| Gross Margin | 97.8% | 97.3% | 98.6% | 97.6% | 95.4% | 91.3% | 92.4% | — |
| Operating Expenses | ||||||||
| Research & Development | $166.1M | $174.6M | $216.6M | $253.3M | $208.8M | $123.0M | $107.1M | $84.9M |
| SG&A Expense | $348.6M | $266.3M | $214.1M | $159.4M | $118.8M | $67.9M | $37.1M | $29.5M |
| Operating Income | $341.0M | $-2.5M | $-103.7M | $-148.4M | $-177.7M | $-174.8M | $-99.5M | $-94.2M |
| Operating Margin | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% |
| Interest Expense | — | — | $108.2M | $99.1M | $59.3M | $14.5M | $11.9M | $9.2M |
| Pretax Income | $267.4M | $-87.0M | $-226.2M | $-244.4M | $-181.8M | $-182.8M | $-108.9M | — |
| Income Tax Expense | $3.5M | $1.9M | $310.0K | $2.7M | $2.3M | $0 | $0 | $0 |
| Net Income | $263.9M | $-88.9M | $-226.5M | $-247.1M | $-184.1M | $-182.8M | $-108.9M | $-101.3M |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1,026.4% | -223.0% | -490.3% |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-940.00 | $-0.98 |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-940.00 | $-0.98 |
| Shares Outstanding (Basic) | 209.9M | 206.7M | 192.2M | 185.9M | 179.1M | 167.3M | — | — |
| Shares Outstanding (Diluted) | 218.6M | 206.7M | 192.2M | 185.9M | 179.1M | 167.3M | 115.6M | 103.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |